Edition:
India

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

210.70CHF
7:05pm IST
Change (% chg)

CHF-1.15 (-0.54%)
Prev Close
CHF211.85
Open
CHF211.25
Day's High
CHF213.55
Day's Low
CHF210.30
Volume
919,261
Avg. Vol
1,914,557
52-wk High
CHF256.40
52-wk Low
CHF206.35

Select another date:

Tue, Jun 5 2018

Roche gets priority review from FDA for Hemlibra

ZURICH, June 5 Roche has been given fast-track review by the U.S. Food and Drug Administration (FDA) for its Hemlibra treatment for people with a form of haemophilia, the Swiss drugmaker said on Tuesday.

Roche's Perjeta wins approval in Europe for expanded use

ZURICH Roche's on Friday won European Union approval for its Perjeta medicine to treat a type of breast cancer whose sufferers are at a high risk of re-occurrence, the Swiss drugmaker said in a statement.

Roche's Perjeta wins approval in Europe for expanded use

ZURICH, June 1 Roche's on Friday won European Union approval for its Perjeta medicine to treat a type of breast cancer whose sufferers are at a high risk of re-occurrence, the Swiss drugmaker said in a statement.

EMA recommends restrictions on Merck, Roche immunotherapies

ZURICH The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they may not work as well as chemotherapy in some patients.

REFILE-EMA recommends restrictions on Merck, Roche immunotherapies

ZURICH, June 1 The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they may not work as well as chemotherapy in some patients.

EMA recommends restrictions on Merck, Roche immunotherapies

ZURICH, June 1 The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they may not work as well as chemotherapy in some patients.

Roche, chasing Merck, notches another lung cancer win

ZURICH Roche's bid to keep Merck's cancer blockbuster Keytruda within striking distance got a lift on Tuesday when the Swiss drugmaker said its immunotherapy Tecentriq mixed with chemotherapy boosted lung cancer patients' survival.

Roche, chasing Merck, notches another lung cancer win

ZURICH Roche's bid to keep Merck's cancer blockbuster Keytruda within striking distance got a lift on Tuesday when the Swiss drugmaker said its immunotherapy Tecentriq mixed with chemotherapy boosted lung cancer patients' survival.

UPDATE 1-Roche, chasing Merck, notches another lung cancer win

* Detailed trial results due later this year (Adds comment from Roche, details, analyst comments)

Vontobel's move for Notenstein shakes up Swiss private banking

ZURICH Private bank Vontobel is buying smaller competitor Notenstein La Roche from Swiss cooperative bank Raiffeisen [RFSHW.UL] for $705 million, the first in what industry insiders expect could be a new wave of consolidation in the sector.

Select another date: